Caprock Group LLC Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Caprock Group LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 16.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 797 shares of the biopharmaceutical company’s stock after selling 153 shares during the quarter. Caprock Group LLC’s holdings in Regeneron Pharmaceuticals were worth $700,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Sunbelt Securities Inc. purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $25,000. Fortitude Family Office LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. Bruce G. Allen Investments LLC purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $40,000. Finally, Sutton Wealth Advisors Inc. raised its position in Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 13 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Joseph L. Goldstein sold 2,707 shares of the firm’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total value of $2,571,650.00. Following the completion of the transaction, the director now owns 6,382 shares of the company’s stock, valued at approximately $6,062,900. The disclosure for this sale can be found here. Insiders sold a total of 13,729 shares of company stock worth $13,124,641 in the last quarter. 8.83% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of analyst reports. TD Cowen increased their price target on Regeneron Pharmaceuticals from $900.00 to $1,000.00 and gave the company an “outperform” rating in a research report on Wednesday, December 6th. Royal Bank of Canada raised their target price on Regeneron Pharmaceuticals from $1,096.00 to $1,184.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. Morgan Stanley raised their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. Sanford C. Bernstein assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price for the company. Finally, Barclays raised their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research report on Tuesday, January 23rd. Four analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $967.59.

Get Our Latest Report on REGN

Regeneron Pharmaceuticals Stock Down 0.4 %

REGN stock opened at $962.49 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The stock has a fifty day moving average of $959.52 and a 200-day moving average of $881.01. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The company has a market capitalization of $105.64 billion, a price-to-earnings ratio of 27.70, a PEG ratio of 2.81 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter last year, the company earned $10.96 EPS. The firm’s revenue was up .6% compared to the same quarter last year. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.18 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.